CD4 and cancer: This is reflected by a stronger selective pressure of mutations in MHC-II-restricted neoantigens compared to MHC-I-restricted neoantigens during tumorigenesis, which reinforces the key contribution of CD4 T cells in cancer immunosurveillance (9).